ITMN was at $50 when investors thought pirfenidone was a shoo-in to be approved by the FDA following a positive vote by the advisory panel. There’s no reason I can see why the stock ought to get back to that level.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”